Alex Hillenbrand

Phase 4 VERDICT data show a 67% lower hazard of UC complications with disease clearance versus symptomatic remission among target achievers.

AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.

Topline data show a 69% placebo-adjusted drop in serum bile acids, with an sNDA planned for the first half of 2027.

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.

Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.

Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.

Hepatology in Q3 2026: brelovitug and lonafarnib advance in hepatitis D, plus Wilson disease, MASH, and US alcohol use updates.

Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.

Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.

Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.

Smoking was associated with greater odds of EPI, and prevalence ranged from 21.1% to 52.1% depending on the diagnostic test used.

Mirum's antibody led to virologic response and ALT normalization in up to 56% of patients at week 24, vs 0% with delayed treatment.

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.

An exploratory analysis of the phase 2 EVITA trial found a survival difference, but abnormal cell growth did not change.

New ASH guidelines recommend higher ferritin thresholds to improve the diagnosis of iron deficiency across key populations.

BEACON-HCC offers a new approach to HCC treatment allocation, with key differences from the updated BCLC framework.

Atacicept also stabilized eGFR and matched placebo on safety, with a full FDA approval filing planned for Q4 2026.

Martin Douglass, PhD, and Vanderbilt colleagues found a Bce module that helps C diff evade bacitracin and host iron restriction

SPY003 cut histologic disease activity by 10 points at 12 weeks, completing proof-of-concept for Spyre's IBD combinations.

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

Hepatology in August 2026: FDA designations for volixibat and lonafarnib, ketogenic diet liver data, and alcohol use in CLD.

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

New RCT finds ketogenic diet cuts liver fat and improves glycemic control more than Mediterranean or plant-forward diets after matched weight loss.

A phase 2 study found the EAP regimen achieved optimal stem cell mobilization in most patients with multiple myeloma or lymphoma, with low plerixafor need.

Daraxonrasib (Rasonque) extended median survival to 13.2 months versus 6.7 months with chemotherapy in a phase 3 trial.

Nipocalimab-aahu (IMAAVY) is now approved for wAIHA, based on Phase 2/3 ENERGY trial data showing durable hemoglobin response.